Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured $265,000 through a share purchase plan (SPP), adding to a broader $20 million capital raising as the company shifts its focus towards commercial expansion of its FebriDx diagnostic platform.
The SPP, which closed on April 24, attracted applications for 1,177,770 new shares at $0.225 each, with participation from existing shareholders including directors Sam Lanyon and Catherine Robson.
The plan complements Lumos’ earlier institutional placement and strengthens its balance sheet as it moves into what management has described as a key growth phase.
Chief executive Doug Ward said the additional funding would help maintain momentum at an “important inflection point” for the business, particularly as it ramps up commercialisation efforts in the United States.
Capital supports FebriDx rollout
Lumos is now targeting a large-scale rollout of its FebriDx rapid diagnostic test across the US, focusing on CLIA-waived healthcare settings such as urgent care clinics and physician offices.
The company estimates this market includes:
- More than 300,000 testing locations
- Around 80 million patients annually presenting with acute respiratory infections
FebriDx delivers results in around 10 minutes and is designed to differentiate between bacterial and non-bacterial infections, supporting more targeted treatment decisions and helping reduce unnecessary antibiotic use.
Ward said the strengthened capital position gives Lumos “the best possible chance” to expand FebriDx uptake and deliver on its broader mission of improving patient care while addressing antimicrobial resistance.
Structure and timing
Under the SPP terms, eligible shareholders could subscribe for up to $30,000 worth of shares, with one free attaching option issued for every two shares subscribed.
Key details include:
- Exercise price of $0.34 per option
- Expiry date of December 31, 2027
The company expects to issue the SPP shares and associated options on May 1, alongside a large tranche of placement options issued on similar terms.
Some director-related options will be subject to shareholder approval at a forthcoming annual general meeting.
Building on recent pivot
The capital raising follows a series of recent updates highlighting Lumos’ strategic shift towards commercial growth, particularly after advancing FebriDx in the US market, with increasing emphasis on sales channels, distribution and real-world adoption.
While the SPP itself delivered a relatively small contribution compared with the institutional placement, it signals continued support from existing shareholders as Lumos looks to scale its core product in a large and competitive healthcare market.